{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:19:39Z","timestamp":1793110779376,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypersensitivity reactions (HSRs) to chemotherapy agents can present a serious challenge to treating patients with preferred or first-line therapies. Allergic reactions through an immunologic mechanism have been established for platinum and taxane agents, which are used to treat a wide variety of cancers including gynecologic cancers. Platin HSRs typically occur after multiple cycles of chemotherapy, reflecting the development of drug IgE sensitization, while taxane HSRs often occur on first or second exposure. Despite observed differences between platin and taxane HSRs, drug desensitization has been an effective method to reintroduce both chemotherapeutic agents safely. Skin testing is the primary diagnostic tool used to risk-stratify patients after initial HSRs, with more widespread use for platinum agents than taxanes. Different practices exist around the use of skin testing, drug challenge, and choice of desensitization protocol. Here, we review the epidemiology, mechanism, and clinical presentation of HSRs to platinum and taxane agents, as well as key controversies in their evaluation and management.<\/jats:p>","DOI":"10.1007\/s12016-021-08877-y","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T11:03:30Z","timestamp":1627902210000},"page":"432-448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Hypersensitivity Reactions to Platinum Agents and Taxanes"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4608-0064","authenticated-orcid":false,"given":"Lulu R.","family":"Tsao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda D.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M.","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana C.","family":"Castells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"8877_CR1","doi-asserted-by":"publisher","unstructured":"Ledermann JA (2018) First-line treatment of ovarian cancer: questions and controversies to address. Ther Adv Med Oncol 10.\u00a0https:\/\/doi.org\/10.1177\/1758835918768232","DOI":"10.1177\/1758835918768232"},{"key":"8877_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.iac.2017.06.003","volume":"37","author":"IM Otani","year":"2017","unstructured":"Otani IM, Wong J, Banerji A (2017) Platinum chemotherapy hypersensitivity. Immunol Allergy Clin North Am 37:663\u2013677. https:\/\/doi.org\/10.1016\/j.iac.2017.06.003","journal-title":"Immunol Allergy Clin North Am"},{"key":"8877_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3747\/co.21.1966","volume":"21","author":"J Boulanger","year":"2014","unstructured":"Boulanger J, Boursiquot JN, Cournoyer G, Lemieux J, Masse MS, Almanric K et al (2014) Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations. Curr Oncol 21:630\u2013641. https:\/\/doi.org\/10.3747\/co.21.1966","journal-title":"Curr Oncol"},{"key":"8877_CR4","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jaci.2009.02.042","volume":"123","author":"PE Hesterberg","year":"2009","unstructured":"Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV et al (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123:1262-1267.e1. https:\/\/doi.org\/10.1016\/j.jaci.2009.02.042","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","volume":"8","author":"J Silver","year":"2020","unstructured":"Silver J, Garcia-Neuer M, Lynch D-M, Pasaoglu G, Sloane DE, Castells M (2020) Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin. J Allergy Clin Immunol Pract 8:1668-1680.e2. https:\/\/doi.org\/10.1016\/j.jaip.2020.02.013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR6","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B et al (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol Off J Am Soc Clin Oncol 17:1141. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1141","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8877_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000055363","volume":"61","author":"A Polyzos","year":"2001","unstructured":"Polyzos A, Tsavaris N, Kosmas C, Arnaouti T, Kalahanis N, Tsigris C et al (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129\u2013133. https:\/\/doi.org\/10.1159\/000055363","journal-title":"Oncology"},{"key":"8877_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/IGC.0b013e3181a1bf2e","volume":"19","author":"H Koshiba","year":"2009","unstructured":"Koshiba H, Hosokawa K, Kubo A, Miyagi Y, Oda T, Miyagi Y et al (2009) Incidence of carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies. Int J Gynecol Cancer 19:460\u2013465. https:\/\/doi.org\/10.1111\/IGC.0b013e3181a1bf2e","journal-title":"Int J Gynecol Cancer"},{"key":"8877_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","volume":"103","author":"M Navo","year":"2006","unstructured":"Navo M, Kunthur A, Badell ML, Coffer LW, Markman M, Brown J et al (2006) Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103:608\u2013613. https:\/\/doi.org\/10.1016\/j.ygyno.2006.04.002","journal-title":"Gynecol Oncol"},{"key":"8877_CR10","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.jaip.2020.08.006","volume":"8","author":"AD Broyles","year":"2020","unstructured":"Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ et al (2020) Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs. J Allergy Clin Immunol Pract 8:S16-116. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.006","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/bjc.2013.389","volume":"109","author":"DH Moon","year":"2013","unstructured":"Moon DH, Lee J-M, Noonan AM, Annunziata CM, Minasian L, Houston N et al (2013) Deleterious BRCA1\/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 109:1072\u20131078. https:\/\/doi.org\/10.1038\/bjc.2013.389","journal-title":"Br J Cancer"},{"key":"8877_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ygyno.2011.04.019","volume":"122","author":"F Joly","year":"2011","unstructured":"Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A et al (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122:226\u2013232. https:\/\/doi.org\/10.1016\/j.ygyno.2011.04.019","journal-title":"Gynecol Oncol"},{"key":"8877_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jaip.2015.07.003","volume":"3","author":"T Lax","year":"2015","unstructured":"Lax T, Long A, Banerji A (2015) Skin testing in the evaluation and management of carboplatin-related hypersensitivity reactions. J Allergy Clin Immunol Pract 3:856\u2013862. https:\/\/doi.org\/10.1016\/j.jaip.2015.07.003","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","volume":"2","author":"JT Wong","year":"2014","unstructured":"Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2:40\u201345. https:\/\/doi.org\/10.1016\/j.jaip.2013.08.011","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12016-014-8416-0","volume":"49","author":"M Picard","year":"2015","unstructured":"Picard M, Castells MC (2015) Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol 49:177\u2013191. https:\/\/doi.org\/10.1007\/s12016-014-8416-0","journal-title":"Clin Rev Allergy Immunol"},{"key":"8877_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol Off J Am Soc Clin Oncol 18:102\u2013105. https:\/\/doi.org\/10.1200\/JCO.2000.18.1.102","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8877_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-004-0924-9","volume":"56","author":"T Sendo","year":"2005","unstructured":"Sendo T, Sakai N, Itoh Y, Ikesue H, Kobayashi H, Hirakawa T et al (2005) Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother Pharmacol 56:91\u201396. https:\/\/doi.org\/10.1007\/s00280-004-0924-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"8877_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12016-016-8556-5","volume":"54","author":"R Bonamichi-Santos","year":"2018","unstructured":"Bonamichi-Santos R, Castells M (2018) Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol 54:375\u2013385. https:\/\/doi.org\/10.1007\/s12016-016-8556-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"8877_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaip.2018.09.018","volume":"7","author":"M Pagani","year":"2019","unstructured":"Pagani M, Bavbek S, Dursun AB, Bonadonna P, Caralli M, Cernadas J et al (2019) Role of skin tests in the diagnosis of immediate hypersensitivity reactions to taxanes: results of a multicenter study. J Allergy Clin Immunol Pract 7:990\u2013997. https:\/\/doi.org\/10.1016\/j.jaip.2018.09.018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR20","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","volume":"96","author":"AM Feldweg","year":"2005","unstructured":"Feldweg AM, Lee C-W, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96:824\u2013829. https:\/\/doi.org\/10.1016\/j.ygyno.2004.11.043","journal-title":"Gynecol Oncol"},{"key":"8877_CR21","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1016\/j.jaip.2020.08.005","volume":"8","author":"DI Hong","year":"2020","unstructured":"Hong DI, Madrigal-Burgaleta R, Banerji A, Castells M, Alvarez-Cuesta E (2020) Controversies in allergy: chemotherapy reactions, desensitize, or delabel? J Allergy Clin Immunol Pract 8:2907\u20132915.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.08.005","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR22","unstructured":"Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8:1038\u20131044"},{"key":"8877_CR23","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/JCO.2005.11.013","volume":"23","author":"NK Ibrahim","year":"2005","unstructured":"Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC et al (2005) Multicenter phase ii trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019\u20136026. https:\/\/doi.org\/10.1200\/JCO.2005.11.013","journal-title":"J Clin Oncol"},{"key":"8877_CR24","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer. J Clin Oncol 23:7794\u20137803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937","journal-title":"J Clin Oncol"},{"key":"8877_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jff.2008.09.004","volume":"1","author":"A Hoffman","year":"2009","unstructured":"Hoffman A, Shahidi F (2009) Paclitaxel and other taxanes in hazelnut. J Funct Foods 1:33\u201337. https:\/\/doi.org\/10.1016\/j.jff.2008.09.004","journal-title":"J Funct Foods"},{"key":"8877_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/1078155207077926","volume":"13","author":"DG Bukacel","year":"2007","unstructured":"Bukacel DG, Bander R, Ibrahim RB (2007) Cross-reactivity between paclitaxel and hazelnut: a case report. J Oncol Pharm Pract 13:53\u201355. https:\/\/doi.org\/10.1177\/1078155207077926","journal-title":"J Oncol Pharm Pract"},{"key":"8877_CR27","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaip.2017.08.025","volume":"6","author":"IM Otani","year":"2018","unstructured":"Otani IM, Lax T, Long AA, Slawski BR, Camargo CA, Banerji A (2018) Utility of risk stratification for paclitaxel hypersensitivity reactions. J Allergy Clin Immunol Pract 6:1266-1273.e2. https:\/\/doi.org\/10.1016\/j.jaip.2017.08.025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ygyno.2017.03.015","volume":"145","author":"DM O\u2019Malley","year":"2017","unstructured":"O\u2019Malley DM, Vetter MH, Cohn DE, Khan A, Hays JL (2017) Outpatient desensitization in selected patients with platinum hypersensitivity reactions. Gynecol Oncol 145:603\u2013610. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.015","journal-title":"Gynecol Oncol"},{"key":"8877_CR29","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda, Md: National Cancer Institute. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed: March 15, 2021"},{"key":"8877_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaci.2004.04.029","volume":"114","author":"SGA Brown","year":"2004","unstructured":"Brown SGA (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114:371\u2013376. https:\/\/doi.org\/10.1016\/j.jaci.2004.04.029","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR31","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","volume":"4","author":"D Sloane","year":"2016","unstructured":"Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D et al (2016) Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies. J Allergy Clin Immunol Pract 4:497\u2013504. https:\/\/doi.org\/10.1016\/j.jaip.2015.12.019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR32","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","volume":"137","author":"M Picard","year":"2016","unstructured":"Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galv\u00e3o VR, Berlin ST et al (2016) Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 137:1154-1164.e12. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.039","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/all.12620","volume":"70","author":"E Alvarez-Cuesta","year":"2015","unstructured":"Alvarez-Cuesta E, Madrigal-Burgaleta R, Angel-Pereira D, Ure\u00f1a-Tavera A, Zamora-Verduga M, Lopez-Gonzalez P et al (2015) Delving into cornerstones of hypersensitivity to antineoplastic and biological agents: value of diagnostic tools prior to desensitization. Allergy 70:784\u2013794. https:\/\/doi.org\/10.1111\/all.12620","journal-title":"Allergy"},{"key":"8877_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaip.2016.11.006","volume":"5","author":"P Giavina-Bianchi","year":"2017","unstructured":"Giavina-Bianchi P, Galv\u00e3o VR, Picard M, Caiado J, Castells MC (2017) Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds\u2014allergy. J Allergy Clin Immunol Pract 5:728\u2013736. https:\/\/doi.org\/10.1016\/j.jaip.2016.11.006","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR35","doi-asserted-by":"publisher","unstructured":"Mo\u00f1ino-Romero S, Vecillas L de las, Alenazy LA, Labella M, Sz\u00e9pfalusi Z, Fiebiger E et al (2020) Soluble Fc\u03b5RI, IgE, and tryptase as potential biomarkers of rapid desensitizations for platin IgE sensitized cancer patients. J Allergy Clin Immunol Pract 8:2085\u20132088.e10. https:\/\/doi.org\/10.1016\/j.jaip.2020.01.047","DOI":"10.1016\/j.jaip.2020.01.047"},{"key":"8877_CR36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jaci.2011.10.010","volume":"129","author":"SU Patil","year":"2012","unstructured":"Patil SU, Long AA, Ling M, Wilson MT, Hesterberg P, Wong JT et al (2012) A protocol for risk stratification of patients with carboplatin-induced hypersensitivity reactions. J Allergy Clin Immunol 129:443\u2013447. https:\/\/doi.org\/10.1016\/j.jaci.2011.10.010","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2015.07.017","volume":"115","author":"AL Wang","year":"2015","unstructured":"Wang AL, Patil SU, Long AA, Banerji A (2015) Risk-stratification protocol for carboplatin and oxaliplatin hypersensitivity: repeat skin testing to identify drug allergy. Ann Allergy Asthma Immunol 115:422\u2013428. https:\/\/doi.org\/10.1016\/j.anai.2015.07.017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8877_CR38","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1200\/JCO.2003.05.539","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J (2003) Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 21:4611\u20134614. https:\/\/doi.org\/10.1200\/JCO.2003.05.539","journal-title":"J Clin Oncol"},{"key":"8877_CR39","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.jaip.2019.12.032","volume":"8","author":"J Pradelli","year":"2020","unstructured":"Pradelli J, Verdoire P, Boutros J, Frin A-C, Follana P, Duquesne J et al (2020) Allergy evaluation of hypersensitivity to platinum salts and taxanes: a six-year experience. J Allergy Clin Immunol Pract 8:1658\u20131664. https:\/\/doi.org\/10.1016\/j.jaip.2019.12.032","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR40","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jaip.2019.08.055","volume":"8","author":"AS Levin","year":"2020","unstructured":"Levin AS, Slawski B, Camargo CA, Banerji A (2020) Platin risk stratification algorithm with modified intradermal skin test protocol. J Allergy Clin Immunol Pract 8:1139\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2019.08.055","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR41","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Ida Hsu F, Barrett NA, Hong DI et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574\u2013580. https:\/\/doi.org\/10.1016\/j.jaci.2008.02.044","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR42","doi-asserted-by":"publisher","unstructured":"Hong DIC (2019)\u00a0 Desensitization for allergic reactions to chemotherapy. Yonsei Med J 60:119\u2013125. https:\/\/doi.org\/10.3349\/ymj.2019.60.2.119","DOI":"10.3349\/ymj.2019.60.2.119"},{"key":"8877_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdj042","volume":"17","author":"SWK Siu","year":"2006","unstructured":"Siu SWK, Chan RTT, Au GKH (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259\u2013261. https:\/\/doi.org\/10.1093\/annonc\/mdj042","journal-title":"Ann Oncol"},{"key":"8877_CR44","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","volume":"2","author":"A Banerji","year":"2014","unstructured":"Banerji A, Lax T, Guyer A, Hurwitz S, Camargo CA, Long AA (2014) Management of hypersensitivity reactions to carboplatin and paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2:428\u2013433. https:\/\/doi.org\/10.1016\/j.jaip.2014.04.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR45","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","volume":"7","author":"R Madrigal-Burgaleta","year":"2019","unstructured":"Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E (2019) A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract 7:618\u2013632. https:\/\/doi.org\/10.1016\/j.jaip.2018.07.031","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR46","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaip.2020.11.021","volume":"9","author":"P V\u00e1zquez-Revuelta","year":"2021","unstructured":"V\u00e1zquez-Revuelta P, Mart\u00ed-Garrido J, Molina-Mata K, Lleonart-Bellfill R, Rey-Salido M, Madrigal-Burgaleta R (2021) Delabeling patients from chemotherapy and biologics allergy: implementing drug provocation testing. J Allergy Clin Immunol Pract 9:1742\u20131745.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR47","doi-asserted-by":"publisher","unstructured":"Mart\u00ed-Garrido J, V\u00e1zquez-Revuelta P, Lleonart-Bellfill R, Molina-Mata K, Mu\u00f1oz-S\u00e1nchez C, Madrigal-Burgaleta R (2020) Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents. J Investig Allergol Clin Immunol 31:166\u2013168. https:\/\/doi.org\/10.18176\/jiaci.0552","DOI":"10.18176\/jiaci.0552"},{"key":"8877_CR48","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/all.12105","volume":"68","author":"R Madrigal-Burgaleta","year":"2013","unstructured":"Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C et al (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68:853\u2013861. https:\/\/doi.org\/10.1111\/all.12105","journal-title":"Allergy"},{"key":"8877_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1081-1206(10)61136-2","volume":"94","author":"AR Morales","year":"2005","unstructured":"Morales AR, Shah N, Castells M (2005) Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 94:575\u2013580. https:\/\/doi.org\/10.1016\/S1081-1206(10)61136-2","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8877_CR50","doi-asserted-by":"publisher","unstructured":"Sancho-Serra M del C, Simarro M, Castells M. Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting Fc\u03b5RI internalization. Eur J Immunol 2011;41:1004\u201313. https:\/\/doi.org\/10.1002\/eji.201040810","DOI":"10.1002\/eji.201040810"},{"key":"8877_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2004.08.002","volume":"95","author":"C-W Lee","year":"2004","unstructured":"Lee C-W, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell\/IgE-mediated reactions. Gynecol Oncol 95:370\u2013376. https:\/\/doi.org\/10.1016\/j.ygyno.2004.08.002","journal-title":"Gynecol Oncol"},{"key":"8877_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s40521-015-0060-2","volume":"2","author":"P Giavina-Bianchi","year":"2015","unstructured":"Giavina-Bianchi P, Aun MV, Galv\u00e3o VR, Castells M (2015) Rapid desensitization in immediate hypersensitivity reaction to drugs. Curr Treat Options Allergy 2:268\u2013285. https:\/\/doi.org\/10.1007\/s40521-015-0060-2","journal-title":"Curr Treat Options Allergy"},{"key":"8877_CR53","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","volume":"99","author":"C-W Lee","year":"2005","unstructured":"Lee C-W, Matulonis UA, Castells MC (2005) Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99:393\u2013399. https:\/\/doi.org\/10.1016\/j.ygyno.2005.06.028","journal-title":"Gynecol Oncol"},{"key":"8877_CR54","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.anai.2018.01.008","volume":"120","author":"SL Mawhirt","year":"2018","unstructured":"Mawhirt SL, Fonacier LS, Calixte R, Davis-Lorton M, Aquino MR (2018) Skin testing and desensitization outcomes among platinum-sensitive oncology patients. Ann Allergy Asthma Immunol 120:437\u2013439. https:\/\/doi.org\/10.1016\/j.anai.2018.01.008","journal-title":"Ann Allergy Asthma Immunol"},{"key":"8877_CR55","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.jaip.2017.11.033","volume":"6","author":"E P\u00e9rez-Rodr\u00edguez","year":"2018","unstructured":"P\u00e9rez-Rodr\u00edguez E, Mart\u00ednez-Tadeo JA, P\u00e9rez-Rodr\u00edguez N, Hern\u00e1ndez-Santana G, Callero-Viera A, Rodr\u00edguez-Plata E et al (2018) Outcome of 490 desensitizations to chemotherapy drugs with a rapid one-solution protocol. J Allergy Clin Immunol Pract 6:1621\u20131627.e6. https:\/\/doi.org\/10.1016\/j.jaip.2017.11.033","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR56","doi-asserted-by":"publisher","unstructured":"Chung SJ, Kang SY, Kang RY, Kim YC, Lee KH, Kim TY et al (2018) A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity. Cancer Chemother Pharmacol 82:777\u2013785. https:\/\/doi.org\/10.1007\/s00280-018-3662-0","DOI":"10.1007\/s00280-018-3662-0"},{"key":"8877_CR57","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jaip.2019.10.014","volume":"8","author":"J-H Lee","year":"2020","unstructured":"Lee JH, Moon M, Kim YC, Chung SJ, Oh J, Kang DY et al (2020) A one-bag rapid desensitization protocol for paclitaxel hypersensitivity: a noninferior alternative to a multi-bag rapid desensitization protocol. J Allergy Clin Immunol Pract 8:696\u2013703. https:\/\/doi.org\/10.1016\/j.jaip.2019.10.014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ygyno.2018.10.037","volume":"152","author":"MH Vetter","year":"2019","unstructured":"Vetter MH, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ et al (2019) Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol 152:316\u2013321. https:\/\/doi.org\/10.1016\/j.ygyno.2018.10.037","journal-title":"Gynecol Oncol"},{"key":"8877_CR59","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","volume":"8","author":"M Castells","year":"2017","unstructured":"Castells M (2017) Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front Immunol 8:1472. https:\/\/doi.org\/10.3389\/fimmu.2017.01472","journal-title":"Front Immunol"},{"key":"8877_CR60","doi-asserted-by":"publisher","unstructured":"Isabwe GAC, Garcia Neuer M, de Las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M (2018) Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol 142:159\u2013170.e2. https:\/\/doi.org\/10.1016\/j.jaci.2018.02.018","DOI":"10.1016\/j.jaci.2018.02.018"},{"key":"8877_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jaip.2016.07.010","volume":"5","author":"T Lax","year":"2017","unstructured":"Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A et al (2017) Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract 5:177\u2013178. https:\/\/doi.org\/10.1016\/j.jaip.2016.07.010","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8877_CR62","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1097\/IGC.0000000000001280","volume":"28","author":"K LaVigne","year":"2018","unstructured":"LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C et al (2018) A randomized trial of prophylactic extended carboplatin infusion to reduce hypersensitivity reactions in recurrent ovarian cancer. Int J Gynecol Cancer 28:1176\u20131182. https:\/\/doi.org\/10.1097\/IGC.0000000000001280","journal-title":"Int J Gynecol Cancer"},{"key":"8877_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2014.07.104","volume":"135","author":"Q Li","year":"2014","unstructured":"Li Q, Cohn D, Waller A, Backes F, Copeland L, Fowler J et al (2014) Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin\/cisplatin. Gynecol Oncol 135:90\u201394. https:\/\/doi.org\/10.1016\/j.ygyno.2014.07.104","journal-title":"Gynecol Oncol"},{"key":"8877_CR64","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2016.09.027","volume":"144","author":"G Altwerger","year":"2017","unstructured":"Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA et al (2017) Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Gynecol Oncol 144:77\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2016.09.027","journal-title":"Gynecol Oncol"},{"key":"8877_CR65","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jaci.2017.06.012","volume":"140","author":"M Castells","year":"2017","unstructured":"Castells M (2017) Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol 140:321\u2013333. https:\/\/doi.org\/10.1016\/j.jaci.2017.06.012","journal-title":"J Allergy Clin Immunol"},{"key":"8877_CR66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/(sici)1096-911x(199903)32:3<183::aid-mpo4>3.0.co;2-p","volume":"32","author":"A Schiavetti","year":"1999","unstructured":"Schiavetti A, Varrasso G, Maurizi P, Castello MA (1999) Hypersensitivity to carboplatin in children. Med Pediatr Oncol 32:183\u2013185. https:\/\/doi.org\/10.1002\/(sici)1096-911x(199903)32:3%3c183::aid-mpo4%3e3.0.co;2-p","journal-title":"Med Pediatr Oncol"},{"key":"8877_CR67","doi-asserted-by":"publisher","unstructured":"Ruggiero A, Rizzo D, Catalano M, Attin\u00e0 G, Riccardi R (2017) Hypersensitivity to carboplatin in children with malignancy. Front Pharmacol 08. https:\/\/doi.org\/10.3389\/fphar.2017.00201","DOI":"10.3389\/fphar.2017.00201"},{"key":"8877_CR68","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.23249","volume":"112","author":"L Lafay-Cousin","year":"2008","unstructured":"Lafay-Cousin L, Sung L, Carret A-S, Hukin J, Wilson B, Johnston DL et al (2008) Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 112:892\u2013899. https:\/\/doi.org\/10.1002\/cncr.23249","journal-title":"Cancer"},{"key":"8877_CR69","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00000421-200212000-00020","volume":"25","author":"C Koren","year":"2002","unstructured":"Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E (2002) Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 25:625\u2013626. https:\/\/doi.org\/10.1097\/00000421-200212000-00020","journal-title":"Am J Clin Oncol"},{"key":"8877_CR70","doi-asserted-by":"publisher","unstructured":"Pivot X, Koralewski P, Hidalgo JL, Chan A, Gon\u00e7alves A, Schwartsmann G et al (2008) A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547\u201352. https:\/\/doi.org\/10.1093\/annonc\/mdn171","DOI":"10.1093\/annonc\/mdn171"},{"key":"8877_CR71","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet Lond Engl 376:1147\u20131154. https:\/\/doi.org\/10.1016\/S0140-6736(10)61389-X","journal-title":"Lancet Lond Engl"},{"key":"8877_CR72","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2217\/fon.13.256","volume":"10","author":"S Bracarda","year":"2014","unstructured":"Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R et al (2014) Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. Future Oncol 10:975\u2013983. https:\/\/doi.org\/10.2217\/fon.13.256","journal-title":"Future Oncol"},{"key":"8877_CR73","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/all.12142","volume":"68","author":"K Brockow","year":"2013","unstructured":"Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB et al (2013) Skin test concentrations for systemically administered drugs\u2014an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy 68:702\u2013712. https:\/\/doi.org\/10.1111\/all.12142","journal-title":"Allergy"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-021-08877-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-021-08877-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T02:31:11Z","timestamp":1653964271000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-021-08877-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["8877"],"URL":"https:\/\/doi.org\/10.1007\/s12016-021-08877-y","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"13 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}